Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company raises $8 million to fast-track development of medicinal cannabis in Australia

Seven new institutional investors have joined the company’s register.
Medicinal cannabis
THC has a clear strategy for bringing medicinal cannabis to the domestic market

The Hydroponics Company Ltd (ASX:THC) will use $8 million raised in a placement to fast-track development of medicinal cannabis for Australian patients.

Funds will also be used to further invest into the company’s Canadian assets and to provide working capital.

The placement at an issue price of $0.63 was fully subscribed with funds raised from sophisticated and institutional investors.

Significantly, seven new institutional investors have joined the company’s register.

READ: The Hydroponics Company granted Medicinal Cannabis Licence

Ian Mutton, chairman, said: “This rounds off a very successful year since the listing of THC in May 2017.

“The board is looking forward to continue to achieve new milestones throughout 2018.”

The company intends to raise a further $3 million through a share purchase plan for eligible shareholders at the same issue price.

READ: The Hydroponics Company in company making partnership with Israel's BOL Pharm

THC, through wholly owned subsidiary Canndeo Limited, has recently secured supply arrangements with Endoca and BOL Pharma which will provide best in class products for the Australian market.

THC has been awarded two of the three licences required for the production of medicinal cannabis in Australia.

An application for the third licence was submitted to the Office of Drug Control simultaneously with the application for the Medicinal Cannabis licence.

Manufacturing site being developed

The company is continuing the development of an Australian manufacturing site which will provide its own production capability.

Initial work has also started on the development of a medicinal cannabis clinic model.

READ: The Hydroponics Company enters licencing agreement with Canadian leader

In Canada, THC is holding discussions with several companies that specialise in the provision of supplies and services to rapidly growing Canadian cannabis markets.

Canadian subsidiary Crystal Mountain continues to expand its product range with the addition of several agencies that complement the range.

Key milestones delivered

Canndeo, which operates under a pharmaceutical model, has delivered key milestones since THC listed in May this year, such as:

  • International Partner Alliance agreement;
  • Medicinal Cannabis Research Licence Granted July 2017;
  • Clinical Trial partner mandated;
  • Medicinal Cannabis Prescription and Dispensing Portal;
  • Medicinal Cannabis Licence granted October 2017;
  • Manufacturing Licence application lodged;
  • Licensing agreement with National Access Cannabis of Canada; and
  • Significant investment into Australian facilities.
Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

Hydroponics Company Ltd Timeline

Related Articles

DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use